Non-Dilutive Funding for Deep-Tech: Grants, R&D Credits, and Innovation Programs

Every deep-tech founder learns the same hard fact: the science takes longer than one funding round. Advanced materials, semiconductors, biotech, climate hardware — these need years of R&D before a product exists, and equity raised against that long, uncertain stretch is the most expensive money you will ever take.

Non-dilutive funding is the alternative: capital that doesn’t cost you ownership. For research-intensive companies it isn’t a fringe optimization — it’s often the difference between reaching the next milestone on your own terms or raising a down round to get there. This guide maps the toolkit.

The three sources

Non-dilutive funding for deep-tech comes from three broad places, each with a different shape:

The art is sequencing them — using grants to fund a specific leap, R&D credits to recover the ongoing burn, and innovation programs for validation and matched capital — so equity is reserved for what only equity can buy: scaling something that already works.

R&D tax credits: the recurring engine

Of the three, R&D tax credits are the most reliable, because they recur every year you do qualifying work. Most major economies run one — Canada’s SR&ED, the UK’s R&D relief, the US Section 41 credit, France’s CIR, Australia’s R&DTI — and several pay cash to pre-revenue companies rather than only offsetting a tax bill. That cash-back design is what turns a tax mechanism into genuine runway.

The single most important nuance is refundability — whether you receive cash even when you owe no tax. For a loss-making research company, a refundable credit is funding; a non-refundable one is a promise against future profit. We cover the country-by-country detail, including which programs pay cash to pre-revenue firms, in the R&D tax credits by country guide.

Grants: funding the specific leap

Grants fund defined objectives — a prototype, a pilot, a specific technical milestone. They’re powerful but lumpy: competitive to win, restricted in use, and heavy on reporting. They suit a discrete leap with a clear deliverable, less so the continuous burn of a research team. The reporting burden also previews something every non-dilutive source eventually demands: evidence.

Innovation programs: validation and matched capital

Accelerators, government co-investment schemes, challenge prizes, and public innovation funds offer capital plus something equity rounds don’t — validation, networks, and sometimes matched funding that stretches every dollar you do raise. They vary enormously by country and sector, and they reward companies that can clearly articulate the technical risk they’re retiring.

The thread through all three: defensible evidence

Whatever the source, non-dilutive funding rewards the same thing: a documented, defensible record of the R&D you actually did — what technical uncertainty you were resolving, who worked on it, and what it cost. Grants demand it in milestone reports. R&D credits demand it under audit. Innovation programs demand it in selection.

And it’s the same evidence, regardless of country or program. The claim rules differ everywhere; the underlying proof — contemporaneous records of who did what experimental work — does not. That evidence rarely lives in a finance system; it lives in the delivery record, captured as the work happens. Reconstructing it after the fact is where claims get thin, grants get clawed back, and audits get painful.

For what specifically qualifies as R&D and how to evidence it, see what counts as R&D.